https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43455 p < 0.001); whilst those with an unhealthy diet and no MVM or fish oil consumption were associated with a higher risk of obesity (p < 0.05). Compared to participants with a long-term healthy diet and no calcium consumption, the combination of a long-term healthy diet and calcium consumption was linked to a lower risk of CVD (IRR = 0.87, 95% CI: 0.78; 0.96). In conclusion, a long-term healthy diet combined with MVM or fish oil was associated with a lower incidence of CVD. Participants who maintained a healthy diet and used calcium supplements were associated with a lower incidence of obesity. However, these associations were not found among those with an unhealthy diet, despite taking similar supplements.]]> Wed 28 Sep 2022 14:35:09 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43746 Wed 28 Sep 2022 10:57:43 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52475 Wed 28 Feb 2024 15:33:43 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53520 28.4 ng/mL) was independently associated with older age, use of beta-blockers, and number of MACE events within a 1 year period. In this patient cohort, elevated sST2 levels are associated with unplanned hospital admission due to MACE within 1 year, independent of the nature of the index cardiovascular admission.]]> Wed 28 Feb 2024 15:31:59 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45264 Wed 26 Oct 2022 18:09:09 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45164 Wed 26 Oct 2022 14:11:30 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48902 Wed 19 Apr 2023 16:30:23 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29617 n = 20 females, n = 22 males). OPS videomicroscopy (Microscan) was used to view ear conch skin microcirculation at 6, 24, and 72 h of age. Stored video was analyzed by a masked observer using proprietary software. There were no significant differences between the sexes for any structural parameters at any time point. There was a significant increase over time in small vessel perfusion in female infants only (P = 0.009). A number of 6- and 72-h measurements were significantly correlated, but differed from the 24-h values. These observations confirm the utility of the ear conch for neonatal microvascular videomicroscopy. They provide a baseline for studies into the use of OPS videomicroscopy in infants. The changes observed are comparable with previous studies of term infants using these and other microvascular techniques. It is recommended that studies for examining the mature neonatal microvascular structure be delayed until 72 h of life, but studies of the physiology of cardiovascular transition should include the 24-h time point after delivery.]]> Wed 11 Apr 2018 16:42:43 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21280 Wed 11 Apr 2018 15:21:40 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:16581 Wed 11 Apr 2018 14:11:56 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14544 Wed 11 Apr 2018 10:15:20 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30654 Wed 11 Apr 2018 09:39:59 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23430 Wed 11 Apr 2018 09:39:20 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29571 18 years) who completed an Australian family-based CVD risk reduction program were invited to a semi-structured telephone interview. Responses were recorded, transcribed verbatim and analysed using a systematic deductive approach with coding derived from key concepts developed as part of the interview structure. Seventeen participants from eight families were interviewed (aged 18-70 years, 47% male, five with CVD diagnosis). Key themes indicated both intrinsic and extrinsic motivations to improve heart health, variations in risk perception, recognition of the role diet plays in heart health, and the extent of family influences on eating patterns. Discrepancies between perceived and actual CVD risk perception impacted on perceived "need" to modify current dietary patterns towards heart health recommendations. Therefore, strategies not reliant on risk perception are needed to engage those with low risk perception. This could involve identifying and accessing the family "ringleader" to influence involvement and capitalising on personal accountability to other family members.]]> Wed 02 Oct 2019 10:22:05 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45364 Thu 27 Oct 2022 15:35:45 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45227 Thu 27 Oct 2022 12:13:04 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26762 Thu 24 Mar 2022 11:35:38 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30888 Thu 09 Dec 2021 11:03:11 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:1063 Sat 24 Mar 2018 08:32:12 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:2491 Sat 24 Mar 2018 08:27:44 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10648 Sat 24 Mar 2018 08:13:40 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10665 Sat 24 Mar 2018 08:12:41 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12190 Sat 24 Mar 2018 08:08:27 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:5331 Sat 24 Mar 2018 07:45:55 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29078 Sat 24 Mar 2018 07:39:58 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28319 Ganoderma lucidum (also known as lingzhi or reishi) is a mushroom that has been consumed for its broad medicinal properties in Asia for over 2000 years. G lucidum is becoming increasingly popular in western countries as a complementary medicine for cardiovascular health. Objectives: To evaluate the effectiveness of G lucidum for the treatment of pharmacologically modifiable risk factors of cardiovascular disease in adults.Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL Issue 6 of 12, 2014) on The Cochrane Library, MEDLINE (OVID, 1946 to June week 3 2014), EMBASE (OVID, 1980 to 2014 week 26), Science Direct (1823 to 2013), Current Controlled Trials (1990 to 2013), Australian New Zealand Clinical Trials Registry (2005 to 2013), Chinese Biomedical Literature Database (2007 to 2013), Chinese Medical Current Contents (2007 to 2013) and other databases. We checked reference lists of included studies, contacted content experts and handsearched The International Journal of Medicinal Mushrooms. We applied no language or publication restrictions. Selection criteria: Randomised controlled trials and controlled clinical trials of G lucidum for the treatment of cardiovascular risk factors. Primary outcomes were blood glucose level, blood pressure and lipid profile. Data collection and analysis: Two authors independently selected trials, assessed risk of bias and cross checked data extraction and analysis. A third author arbitrated in the event of disagreement. Main results: Five trials with a total of 398 participants were eligible for inclusion. Of these, one study was published in Chinese and translated to English; one study was published but study authors provided the additional data used in this review; one study was unpublished and the study authors provided data; and two studies did not provide comparison group data suitable for statistical analyses. The three studies from which data were used for statistical analyses compared G lucidum (1.4 g to 3 g per day) to placebo over 12 to 16 weeks of intervention. Although inclusion criteria varied, all participants of these three studies had type 2 diabetes mellitus. Of the five included studies, risk of bias was low for one study and unclear for the remaining four. Results from two studies showed that G lucidum was not associated with statistically or clinically significant reduction in HbA1c (WMD -0.10%; 95% CI -1.05% to 0.85%; 130 participants), total cholesterol (WMD -0.07mmol/L; 95% CI -0.57 mmol/L to 0.42 mmol/L; 107 participants ), low-density lipoprotein cholesterol (WMD 0.02 mmol/L; 95% CI -0.41 mmol/L to 0.45 mmol/L; 107 participants), or body-mass index (WMD -0.32 kg/m²; 95% CI -2.67 kg/m² to 2.03 kg/m²; 107 participants). All other analyses were from a single study of 84 participants. We found no improvement for fasting plasma glucose (WMD 0.30 mmol/L; 95% CI -0.95 mmol/L to 1.55 mmol/L). Measures of post-prandial blood glucose level found inconsistent results, being in favour of placebo for '2-hour post-prandial blood glucose' (WMD 0.7 mmol/L; 95% CI 0.29 mmol/L to 1.11 mmol/L) and in favour of G lucidum for 'plasma glucose under the curve at 4th hour' (WMD -49.4mg/dL/h; 95% CI -77.21 mg/dL/h to -21.59 mg/dL/h). As the Minimal Clinical Important Differences are unknown, the clinical significance of this effect is unclear. There were no statistically significant differences between groups for blood pressure or triglycerides. Participants who took G lucidum for four months were 1.67 times (RR 1.67 95% CI 0.86 to 3.24) more likely to experience an adverse event than those who took placebo but these were not serious side effects. Authors' conclusions: Evidence from a small number of randomised controlled trials does not support the use of G lucidum for treatment of cardiovascular risk factors in people with type 2 diabetes mellitus. Future research into the efficacy of G lucidum should be placebo-controlled and adhere to clinical trial reporting standards.]]> Sat 24 Mar 2018 07:25:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:3631 Sat 24 Mar 2018 07:21:27 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24871 Sat 24 Mar 2018 07:11:21 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49532 Mon 22 May 2023 08:38:25 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41989 Mon 04 Sep 2023 14:45:22 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41821 2.2 mm. Conclusions: Nurses can lead the assessment of RA occlusion using ultrasound to enhance planning and care, including monitoring compression times to reduce RAO.]]> Fri 12 Aug 2022 12:52:20 AEST ]]>